Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 1996

View Archived Issues

Takeda discloses new agents for neurodegenerative disorders

New antioxidant from Shiseido shows CNS activity

New cardiovascular agents claimed by Hoechst

New taxane derivatives from Rhone-Poulenc Rorer

New NO inhibitors disclosed by Fujisawa

Japanese researchers describe orally active antihypertensive agents

Chugai discloses erythromycins for gastrointestinal disorders

Company Profile: Abgenix

Company profile: BioNumerik

Company profile: Corixa

Company profile: Forbes Medi-Tech

Clinical results reported for rhIGF-I in ALS patients

Ebselen on track for NDA filing in Japan

Agreement reached for atorvastatin development in Japan

XOMA receives U.S. patents covering BPI-related products

Water-soluble fiber introduced in first market for high cholesterol

Initial human safety studies completed for CoCensys' stroke drug

Children's Hospital of Philadelphia offers antimicrobial peptides for licensing

Potential drug screening invention available for licensing

Taiho antirheumatic agent possesses novel mechanism of action

Fujisawa antidementia agent in clinical stage

First approval for Aricept

New biochemical marker for Alzheimer's disease identified

FDA clears treatment for bulimia

FDA approves Amphotec

Trinity Biotech obtains license option for hepatitis A antigens

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026